Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Philip N Sambrook; Christian Roux; Jean-Pierre Devogelaer; Kenneth Saag; Chak-Sing Lau; Jean-Yves Reginster; Christina Bucci-Rechtweg; Guoqin Su; David M Reid

doi:10.1016/j.bone.2011.10.024

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Philip N Sambrook, Christian Roux, Jean-Pierre Devogelaer, Kenneth Saag, Chak-Sing Lau, Jean-Yves Reginster, Christina Bucci-Rechtweg, Guoqin Su, David M Reid

Applied Medicine

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

Abstract

We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).

Original language	English
Pages (from-to)	289-295
Number of pages	7
Journal	Bone
Volume	50
Issue number	1
DOIs	https://doi.org/10.1016/j.bone.2011.10.024 https://doi.org/10.1016/j.bone.2011.12.006
Publication status	Published - Jan 2012

Access to Document

Fingerprint Dive into the research topics of 'Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate'. Together they form a unique fingerprint.

Cite this

Sambrook, P. N., Roux, C., Devogelaer, J-P., Saag, K., Lau, C-S., Reginster, J-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012). Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone, 50(1), 289-295. https://doi.org/10.1016/j.bone.2011.10.024, https://doi.org/10.1016/j.bone.2011.12.006

Bisphosphonates and glucocorticoid osteoporosis in men : results of a randomized controlled trial comparing zoledronic acid with risedronate. / Sambrook, Philip N; Roux, Christian; Devogelaer, Jean-Pierre; Saag, Kenneth; Lau, Chak-Sing; Reginster, Jean-Yves; Bucci-Rechtweg, Christina; Su, Guoqin; Reid, David M.

In: Bone, Vol. 50, No. 1, 01.2012, p. 289-295.

Research output: Contribution to journal › Article › peer-review

Sambrook, PN, Roux, C, Devogelaer, J-P, Saag, K, Lau, C-S, Reginster, J-Y, Bucci-Rechtweg, C, Su, G & Reid, DM 2012, 'Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate', Bone, vol. 50, no. 1, pp. 289-295. https://doi.org/10.1016/j.bone.2011.10.024, https://doi.org/10.1016/j.bone.2011.12.006

@article{063911a8769842f5858ee442bf8faa24,

title = "Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate",

abstract = "We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).",

author = "Sambrook, {Philip N} and Christian Roux and Jean-Pierre Devogelaer and Kenneth Saag and Chak-Sing Lau and Jean-Yves Reginster and Christina Bucci-Rechtweg and Guoqin Su and Reid, {David M}",

note = "Bone Volume 50, Issue 3, March 2012, Page 811 Corrigendum to “Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate” [Bone 50 (2012) 289-295] https://doi.org/10.1016/j.bone.2011.12.006",

year = "2012",

month = jan,

doi = "10.1016/j.bone.2011.10.024",

language = "English",

volume = "50",

pages = "289--295",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Bisphosphonates and glucocorticoid osteoporosis in men

T2 - results of a randomized controlled trial comparing zoledronic acid with risedronate

AU - Sambrook, Philip N

AU - Roux, Christian

AU - Devogelaer, Jean-Pierre

AU - Saag, Kenneth

AU - Lau, Chak-Sing

AU - Reginster, Jean-Yves

AU - Bucci-Rechtweg, Christina

AU - Su, Guoqin

AU - Reid, David M

N1 - Bone Volume 50, Issue 3, March 2012, Page 811 Corrigendum to “Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate” [Bone 50 (2012) 289-295] https://doi.org/10.1016/j.bone.2011.12.006

PY - 2012/1

Y1 - 2012/1

N2 - We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).

AB - We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).

U2 - 10.1016/j.bone.2011.10.024

DO - 10.1016/j.bone.2011.10.024

M3 - Article

C2 - 22061864

VL - 50

SP - 289

EP - 295

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -